Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials by Gennaro Pagano, Dylan Trundell, Tanya Simuni, Nicola Pavese, Kenneth Marek, Ronald B. Postuma, Nima Shariati, Annabelle Monnet, Emma Moore, Evan W. Davies, Hanno Svoboda, Nathalie Pross, Azad Bonni, Tania Nikolcheva, for the PASADENA Investigators, Prasinezumab Study Group

Get full text

Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson’s disease trials by Gennaro Pagano, Dylan Trundell, Tanya Simuni, Nicola Pavese, Kenneth Marek, Ronald B. Postuma, Nima Shariati, Annabelle Monnet, Emma Moore, Evan W. Davies, Hanno Svoboda, Nathalie Pross, Azad Bonni, Tania Nikolcheva, for the PASADENA Investigators, Prasinezumab Study Group

Get full text

Exploratory digital outcome measures of motor sign progression in Parkinson’s disease patients treated with prasinezumab by Kirsten I. Taylor, Florian Lipsmeier, Marzia A. Scelsi, Ekaterina Volkova-Volkmar, Daria Rukina, Werner Popp, Stefan Lambrecht, Judith Anzures-Cabrera, David Summers, Markus Abt, Annabelle Monnet, Timothy Kilchenmann, Jens Schjodt-Eriksen, Laurent Essioux, Thomas Kustermann, Wagner Zago, Hanno Svoboda, Tania Nikolcheva, Ronald B. Postuma, Gennaro Pagano, Michael Lindemann, PASADENA Investigators, Prasinezumab Study Group

Get full text